The Pro Medicus (ASX: PME) share price is a poor performer so far today, despite the company announcing a positive update. We take a look.
The post Pro Medicus (ASX:PME) share price sinks despite new deal appeared first on The Motley Fool Australia. –
The Pro Medicus Limited (ASX: PME) share price is a poor performer so far on Thursday despite the company providing a positive update. In early morning trade, the health imaging company’s shares are fetching $40.05, down 1.26%.
What was announced?
Investors have been selling Pro Medicus shares regardless of the company’s announced contract win.
According to its release, Pro Medicus’ wholly-owned United Stated subsidiary, Visage Imaging Inc., has signed a deal with The University of Vermont Health Network Inc (UVM).
Under the agreement, Pro Medicus will deploy its Visage 7 Enterprise Imaging Platform across 6 hospitals operated by UVM. It is expected that, once the system is fully functional, a unified diagnostic imaging platform will run across the network. This replaces the existing multiple legacy PACS platforms that are currently being used.
The contract is valid for a period of 8 years and is estimated to generate $14 million in revenue for Pro Medicus.
Rollout of the system is scheduled to commence immediately, with go-live dates targeted for the second half of 2021. The Visage 7 platform will be deployed in the public cloud.
The company noted that the latest deal further expands its United States academic institution footprint. Pro Medicus believes that its transactional licensing model could also lead to further potential sales in the future.
Pro Medicus CEO Dr Sam Hupert commented:
We continue to build momentum in the market with this, our seventh contract win in a row, adding to other recent major announcements.
UVM Health Network is the fourth of these to opt for a cloud-based solution, a trend we see increasing rapidly amongst healthcare systems in North America.
Our pipeline continues to grow. Visage 7 with its proven cloud-native capability provides us with a significant strategic advantage that enables us to address these opportunities across a growing segment of the market both in North America and other regions.
Pro Medicus share price snapshot
Over the last 12 months, the Pro Medicus share price has stormed around 55% higher, with year to date performance delivering gains of around 17%. The company’s shares reached an all-time high of $48.69 last month.
Based on valuation grounds, Pro Medicus commands a market capitalisation of around $4.2 billion, with approximately 104 million shares outstanding.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why CSR, Fonterra, Nearmap, & Pro Medicus shares are dropping
- ASX tech shares are in a world of pain. There might be more to come…
- ASX 200 up 0.45%: Macquarie full year results & REA Group Q3 update
- 2 excellent healthcare ASX shares with strong long term growth potential
- 2 highly rated ASX growth shares for May
Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.